BE879666A - NOVEL CEPHALOSPORINS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM - Google Patents

NOVEL CEPHALOSPORINS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Download PDF

Info

Publication number
BE879666A
BE879666A BE0/197842A BE197842A BE879666A BE 879666 A BE879666 A BE 879666A BE 0/197842 A BE0/197842 A BE 0/197842A BE 197842 A BE197842 A BE 197842A BE 879666 A BE879666 A BE 879666A
Authority
BE
Belgium
Prior art keywords
emi
preparation
compositions containing
novel cephalosporins
cephalosporins
Prior art date
Application number
BE0/197842A
Other languages
French (fr)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BE879666A publication Critical patent/BE879666A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Description

       

   <EMI ID=1.1> 

  
compositions les contenant   <EMI ID=2.1> 

  
 <EMI ID=3.1> 

  
pénicillines. Dans certaines circonstances, 

  
souhaitable d'utiliser une céphalosporine qui fasse

  
 <EMI ID=4.1> 

  
 <EMI ID=5.1> 

  
 <EMI ID=6.1> 

  
 <EMI ID=7.1> 

  
large spectre. - '  <EMI ID=8.1>   <EMI ID=9.1> 

  

 <EMI ID=10.1> 


  
 <EMI ID=11.1>   <EMI ID=12.1> 

  
antibiotiques type des céphalosporines dans les-

  
 <EMI ID=13.1> 

  
 <EMI ID=14.1> 

  
 <EMI ID=15.1> 

  
 <EMI ID=16.1> 

  
 <EMI ID=17.1> 

  
éventuellement substitué susmentionné est un radical

  
 <EMI ID=18.1> 

  
Quant ja;rla position 3, elle porte, parmi de nombreux . dès radicaux mono- 

  
 <EMI ID=19.1> 

  
est  oqu 

  
 <EMI ID=20.1>  

  
-aucun <EMI ID=21.1> 

  
 <EMI ID=22.1> 

  
 <EMI ID=23.1> 

  
 <EMI ID=24.1> 

  
 <EMI ID=25.1> 

  
activité tout particulièrement avantageuse (décrite plus en détail dans la suite du présent mémoire). contre toute

  
 <EMI ID=26.1> 

  

 <EMI ID=27.1> 


  
 <EMI ID=28.1>   <EMI ID=29.1> 

  
 <EMI ID=30.1> 

  
 <EMI ID=31.1> 
 <EMI ID=32.1> 
 par rapport au groupe car, Dans présent 

  
 <EMI ID=33.1> 

  
structure comme suit : 

  

 <EMI ID=34.1> 


  
 <EMI ID=35.1> 

  
les conformes invention sont des isomères 

  
 <EMI ID=36.1> 

  
 <EMI ID=37.1>   <EMI ID=38.1> 

  
 <EMI ID=39.1> 

  
 <EMI ID=40.1> 

  
 <EMI ID=41.1> 

  
portée de l'invention s'étend aussi bien aux 

  
 <EMI ID=42.1> 

  
Les composés suivant l'invention font 

  
 <EMI ID=43.1>   <EMI ID=44.1>   <EMI ID=45.1>  <EMI ID=46.1> 

  
 <EMI ID=47.1> 

  
solubles (par exemple des sels métaux alcalins, 

  
 <EMI ID=48.1> 

  
 <EMI ID=49.1> 

  
 <EMI ID=50.1>   <EMI ID=51.1> 

M MOI, 

  
 <EMI ID=52.1> 

  
 <EMI ID=53.1> 

  
 <EMI ID=54.1> 

  
 <EMI ID=55.1> 
-carbone auquel ils sont attachés. 

  
 <EMI ID=56.1> 

  
 <EMI ID=57.1> 

  
 <EMI ID=58.1>   <EMI ID=59.1> 

  

 <EMI ID=60.1> 


  
 <EMI ID=61.1> 

  
 <EMI ID=62.1>  

  

 <EMI ID=63.1> 


  
 <EMI ID=64.1>  
 <EMI ID=65.1> 
 <EMI ID=66.1> 

  

 <EMI ID=67.1> 


  
 <EMI ID=68.1>   <EMI ID=69.1>  sur un composé de la formule 

  

 <EMI ID=70.1> 


  
 <EMI ID=71.1> 

  
 <EMI ID=72.1> 

  

 <EMI ID=73.1> 


  
 <EMI ID=74.1>   <EMI ID=75.1>   <EMI ID=76.1>  

  
 <EMI ID=77.1> 

  
exemple, on peut nient chlorures 

  
 <EMI ID=78.1>  <EMI ID=79.1>  . les réactifs en solution ou suspension. effectue  avantageusement la réaction utilisant  <EMI ID=80.1> 

  
 <EMI ID=81.1> 

  
 <EMI ID=82.1> 

  
 <EMI ID=83.1> 

  
 <EMI ID=84.1> 

  
 <EMI ID=85.1> 

  
 <EMI ID=86.1> 

  
 <EMI ID=87.1>   <EMI ID=88.1> 

  
 <EMI ID=89.1> 

  
 <EMI ID=90.1> 

  
 <EMI ID=91.1> 

  
 <EMI ID=92.1> 

  
 <EMI ID=93.1> 

  
 <EMI ID=94.1> 

  
 <EMI ID=95.1> 

  
 <EMI ID=96.1> 

  
 <EMI ID=97.1> 

  
 <EMI ID=98.1> 

  
 <EMI ID=99.1> 

  
 <EMI ID=100.1> 

  
 <EMI ID=101.1> 

  
 <EMI ID=102.1>  

  
 <EMI ID=103.1> 

  
milieu non. aqueux qui comprend, préférence, -on 

  
 <EMI ID=104.1> 

  
 <EMI ID=105.1>  <EMI ID=106.1> 

  
tant l'anion voulu,

  
+se des composés formule

  
 <EMI ID=107.1>  

  
 <EMI ID=108.1> 

  

 <EMI ID=109.1> 


  
 <EMI ID=110.1>   <EMI ID=111.1> 

  
 <EMI ID=112.1> 

  
 <EMI ID=113.1> 

  
 <EMI ID=114.1> 

  
 <EMI ID=115.1> 

  
 <EMI ID=116.1>   <EMI ID=117.1> 

  
 <EMI ID=118.1> 

  
 <EMI ID=119.1> 

  
Pour 'utilisation titre matières 

  
 <EMI ID=120.1> 

  
 <EMI ID=121.1> 

  
 <EMI ID=122.1> 

  
 <EMI ID=123.1> 

  
On peut préparer les acides de formule

  
 <EMI ID=124.1> 

  
 <EMI ID=125.1> 

  
 <EMI ID=126.1> 

  

 <EMI ID=127.1> 
 

  
(dans laquelle possède les signifierons, précitées ; 

  
 <EMI ID=128.1> 

  

 <EMI ID=129.1> 


  
 <EMI ID=130.1> 

  
que 

  
 <EMI ID=131.1> 

  
 <EMI ID=132.1> 

  
 <EMI ID=133.1>  <EMI ID=134.1> 

  
 <EMI ID=135.1>  

  

 <EMI ID=136.1> 


  
 <EMI ID=137.1> 

  
 <EMI ID=138.1> 

  

 <EMI ID=139.1> 


  
 <EMI ID=140.1>   <EMI ID=141.1>  peuvent se préparer par acylation des composés

  
 <EMI ID=142.1> 

  
 <EMI ID=143.1>   <EMI ID=144.1> 

  
thiourée. 

  
 <EMI ID=145.1>   <EMI ID=146.1>  

  
 <EMI ID=147.1>  

  
 <EMI ID=148.1>   <EMI ID=149.1> 

  
 <EMI ID=150.1> 

  
 <EMI ID=151.1> 

  
 <EMI ID=152.1>   <EMI ID=153.1>   <EMI ID=154.1>  

  
 <EMI ID=155.1>  <EMI ID=156.1> 

  
 <EMI ID=157.1>   <EMI ID=158.1> 

  
une, minute. 

  
 <EMI ID=159.1> 

  
 <EMI ID=160.1> 

  
 <EMI ID=161.1> 

  
 <EMI ID=162.1>   <EMI ID=163.1>   <EMI ID=164.1>   <EMI ID=165.1>   <EMI ID=166.1>   <EMI ID=167.1>   <EMI ID=168.1>   <EMI ID=169.1>  &#65533;&#65533;&#65533;'&#65533;.'&#65533;'â&#65533;&#65533;&#65533;-&#65533;&#65533;&#65533; 

  
 <EMI ID=170.1> 

  
les,- les séchés 

  
 <EMI ID=171.1>   <EMI ID=172.1> 

  
 <EMI ID=173.1>  <EMI ID=174.1> 

  
 <EMI ID=175.1>   <EMI ID=176.1>  <EMI ID=177.1> 

  
 <EMI ID=178.1>   <EMI ID=179.1> 

  
 <EMI ID=180.1> 

  
 <EMI ID=181.1> 

  
 <EMI ID=182.1>   <EMI ID=183.1> 

  
exiger des doses quotidiennes supérieures. 

  
Les antibiotiques conformes présente

  
 <EMI ID=184.1> 

  
 <EMI ID=185.1> 

  
tiques, par exemple des pénicillines d'autres . &#65533;e&#65533;s&#65533;.&#65533;.os&#65533;aa&#65533;&#65533;z&#65533;es. 

  
La composition qui suit, illustre façon..

  
 <EMI ID=186.1> 

  
 <EMI ID=187.1> 

  
 <EMI ID=188.1> 

  
 <EMI ID=189.1> 

  

 <EMI ID=190.1> 


  
 <EMI ID=191.1>   <EMI ID=192.1>   <EMI ID=193.1> 

  

 <EMI ID=194.1> 


  
 <EMI ID=195.1> 



   <EMI ID = 1.1>

  
compositions containing them <EMI ID = 2.1>

  
 <EMI ID = 3.1>

  
penicillins. In certain circumstances,

  
desirable to use a cephalosporin that makes

  
 <EMI ID = 4.1>

  
 <EMI ID = 5.1>

  
 <EMI ID = 6.1>

  
 <EMI ID = 7.1>

  
broad spectrum. - '<EMI ID = 8.1> <EMI ID = 9.1>

  

 <EMI ID = 10.1>


  
 <EMI ID = 11.1> <EMI ID = 12.1>

  
cephalosporin-type antibiotics in

  
 <EMI ID = 13.1>

  
 <EMI ID = 14.1>

  
 <EMI ID = 15.1>

  
 <EMI ID = 16.1>

  
 <EMI ID = 17.1>

  
optionally substituted aforementioned is a radical

  
 <EMI ID = 18.1>

  
As for position 3, it carries, among many. from mono- radicals

  
 <EMI ID = 19.1>

  
is where

  
 <EMI ID = 20.1>

  
-no <EMI ID = 21.1>

  
 <EMI ID = 22.1>

  
 <EMI ID = 23.1>

  
 <EMI ID = 24.1>

  
 <EMI ID = 25.1>

  
particularly advantageous activity (described in more detail later in this memo). against all

  
 <EMI ID = 26.1>

  

 <EMI ID = 27.1>


  
 <EMI ID = 28.1> <EMI ID = 29.1>

  
 <EMI ID = 30.1>

  
 <EMI ID = 31.1>
 <EMI ID = 32.1>
 compared to the group because, in this

  
 <EMI ID = 33.1>

  
structure as follows:

  

 <EMI ID = 34.1>


  
 <EMI ID = 35.1>

  
the conforming invention are isomers

  
 <EMI ID = 36.1>

  
 <EMI ID = 37.1> <EMI ID = 38.1>

  
 <EMI ID = 39.1>

  
 <EMI ID = 40.1>

  
 <EMI ID = 41.1>

  
scope of the invention extends equally to

  
 <EMI ID = 42.1>

  
The compounds according to the invention make

  
 <EMI ID = 43.1> <EMI ID = 44.1> <EMI ID = 45.1> <EMI ID = 46.1>

  
 <EMI ID = 47.1>

  
soluble (e.g. alkali metal salts,

  
 <EMI ID = 48.1>

  
 <EMI ID = 49.1>

  
 <EMI ID = 50.1> <EMI ID = 51.1>

M ME,

  
 <EMI ID = 52.1>

  
 <EMI ID = 53.1>

  
 <EMI ID = 54.1>

  
 <EMI ID = 55.1>
-carbon to which they are attached.

  
 <EMI ID = 56.1>

  
 <EMI ID = 57.1>

  
 <EMI ID = 58.1> <EMI ID = 59.1>

  

 <EMI ID = 60.1>


  
 <EMI ID = 61.1>

  
 <EMI ID = 62.1>

  

 <EMI ID = 63.1>


  
 <EMI ID = 64.1>
 <EMI ID = 65.1>
 <EMI ID = 66.1>

  

 <EMI ID = 67.1>


  
 <EMI ID = 68.1> <EMI ID = 69.1> on a compound of the formula

  

 <EMI ID = 70.1>


  
 <EMI ID = 71.1>

  
 <EMI ID = 72.1>

  

 <EMI ID = 73.1>


  
 <EMI ID = 74.1> <EMI ID = 75.1> <EMI ID = 76.1>

  
 <EMI ID = 77.1>

  
example we can deny chlorides

  
 <EMI ID = 78.1> <EMI ID = 79.1>. reagents in solution or suspension. advantageously performs the reaction using <EMI ID = 80.1>

  
 <EMI ID = 81.1>

  
 <EMI ID = 82.1>

  
 <EMI ID = 83.1>

  
 <EMI ID = 84.1>

  
 <EMI ID = 85.1>

  
 <EMI ID = 86.1>

  
 <EMI ID = 87.1> <EMI ID = 88.1>

  
 <EMI ID = 89.1>

  
 <EMI ID = 90.1>

  
 <EMI ID = 91.1>

  
 <EMI ID = 92.1>

  
 <EMI ID = 93.1>

  
 <EMI ID = 94.1>

  
 <EMI ID = 95.1>

  
 <EMI ID = 96.1>

  
 <EMI ID = 97.1>

  
 <EMI ID = 98.1>

  
 <EMI ID = 99.1>

  
 <EMI ID = 100.1>

  
 <EMI ID = 101.1>

  
 <EMI ID = 102.1>

  
 <EMI ID = 103.1>

  
middle no. aqueous which preferably includes

  
 <EMI ID = 104.1>

  
 <EMI ID = 105.1> <EMI ID = 106.1>

  
so much the desired anion,

  
+ s of the formula compounds

  
 <EMI ID = 107.1>

  
 <EMI ID = 108.1>

  

 <EMI ID = 109.1>


  
 <EMI ID = 110.1> <EMI ID = 111.1>

  
 <EMI ID = 112.1>

  
 <EMI ID = 113.1>

  
 <EMI ID = 114.1>

  
 <EMI ID = 115.1>

  
 <EMI ID = 116.1> <EMI ID = 117.1>

  
 <EMI ID = 118.1>

  
 <EMI ID = 119.1>

  
For 'use title materials

  
 <EMI ID = 120.1>

  
 <EMI ID = 121.1>

  
 <EMI ID = 122.1>

  
 <EMI ID = 123.1>

  
We can prepare the acids of formula

  
 <EMI ID = 124.1>

  
 <EMI ID = 125.1>

  
 <EMI ID = 126.1>

  

 <EMI ID = 127.1>
 

  
(in which has the meanings, mentioned above;

  
 <EMI ID = 128.1>

  

 <EMI ID = 129.1>


  
 <EMI ID = 130.1>

  
than

  
 <EMI ID = 131.1>

  
 <EMI ID = 132.1>

  
 <EMI ID = 133.1> <EMI ID = 134.1>

  
 <EMI ID = 135.1>

  

 <EMI ID = 136.1>


  
 <EMI ID = 137.1>

  
 <EMI ID = 138.1>

  

 <EMI ID = 139.1>


  
 <EMI ID = 140.1> <EMI ID = 141.1> can be prepared by acylation of the compounds

  
 <EMI ID = 142.1>

  
 <EMI ID = 143.1> <EMI ID = 144.1>

  
thiourea.

  
 <EMI ID = 145.1> <EMI ID = 146.1>

  
 <EMI ID = 147.1>

  
 <EMI ID = 148.1> <EMI ID = 149.1>

  
 <EMI ID = 150.1>

  
 <EMI ID = 151.1>

  
 <EMI ID = 152.1> <EMI ID = 153.1> <EMI ID = 154.1>

  
 <EMI ID = 155.1> <EMI ID = 156.1>

  
 <EMI ID = 157.1> <EMI ID = 158.1>

  
one minute.

  
 <EMI ID = 159.1>

  
 <EMI ID = 160.1>

  
 <EMI ID = 161.1>

  
 <EMI ID = 162.1> <EMI ID = 163.1> <EMI ID = 164.1> <EMI ID = 165.1> <EMI ID = 166.1> <EMI ID = 167.1> <EMI ID = 168.1> <EMI ID = 169.1> &#65533; &#65533; &#65533; '&#65533;.' &#65533; 'â &#65533; &#65533; &#65533; - &#65533; &#65533; &#65533;

  
 <EMI ID = 170.1>

  
the, - the dried

  
 <EMI ID = 171.1> <EMI ID = 172.1>

  
 <EMI ID = 173.1> <EMI ID = 174.1>

  
 <EMI ID = 175.1> <EMI ID = 176.1> <EMI ID = 177.1>

  
 <EMI ID = 178.1> <EMI ID = 179.1>

  
 <EMI ID = 180.1>

  
 <EMI ID = 181.1>

  
 <EMI ID = 182.1> <EMI ID = 183.1>

  
require higher daily doses.

  
Compliant Antibiotics Presents

  
 <EMI ID = 184.1>

  
 <EMI ID = 185.1>

  
ticks, for example other penicillins. &#65533; e &#65533; s &#65533;. &#65533; .os &#65533; aa &#65533; &#65533; z &#65533; es.

  
The following composition illustrates how ..

  
 <EMI ID = 186.1>

  
 <EMI ID = 187.1>

  
 <EMI ID = 188.1>

  
 <EMI ID = 189.1>

  

 <EMI ID = 190.1>


  
 <EMI ID = 191.1> <EMI ID = 192.1> <EMI ID = 193.1>

  

 <EMI ID = 194.1>


  
 <EMI ID = 195.1>

Claims (1)

<EMI ID=196.1> <EMI ID=197.1> <EMI ID = 196.1> <EMI ID = 197.1> <EMI ID=198.1> <EMI ID = 198.1> <EMI ID=199.1> <EMI ID = 199.1> <EMI ID=200.1> <EMI ID = 200.1> <EMI ID=201.1> <EMI ID=202.1> <EMI ID = 201.1> <EMI ID = 202.1> <EMI ID=203.1> <EMI ID=204.1> <EMI ID = 203.1> <EMI ID = 204.1> <EMI ID=205.1> <EMI ID = 205.1> <EMI ID=206.1> <EMI ID = 206.1> <EMI ID=207.1> <EMI ID=208.1> <EMI ID = 207.1> <EMI ID = 208.1>
BE0/197842A 1978-10-27 1979-10-26 NOVEL CEPHALOSPORINS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM BE879666A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7842164 1978-10-27

Publications (1)

Publication Number Publication Date
BE879666A true BE879666A (en) 1980-04-28

Family

ID=10500627

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/197842A BE879666A (en) 1978-10-27 1979-10-26 NOVEL CEPHALOSPORINS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

Country Status (4)

Country Link
JP (1) JPS5559197A (en)
AU (1) AU529338B2 (en)
BE (1) BE879666A (en)
ZA (1) ZA795738B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
DE3279470D1 (en) * 1981-04-03 1989-04-06 Fujisawa Pharmaceutical Co New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and their starting compounds
JPS584789A (en) * 1981-04-03 1983-01-11 Fujisawa Pharmaceut Co Ltd Novel cephem compound, its preparation, preventive and remedy for microbism

Also Published As

Publication number Publication date
AU529338B2 (en) 1983-06-02
AU5223979A (en) 1980-05-01
ZA795738B (en) 1980-10-29
JPS5559197A (en) 1980-05-02

Similar Documents

Publication Publication Date Title
Mapson et al. Glutathione reductase from germinated peas
WIELAND et al. Kinetic and regulatory properties of heart muscle pyruvate dehydrogenase
FR2391999A1 (en) CYCLOHEXANE DERIVATIVES FOR USE AS SELECTIVE HERBICIDES
DK165004C (en) SULPHAMATE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
LU83376A1 (en) NOVEL IMIDAZO-RIFAMYCIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY
EP2486020B1 (en) Method for the synthesis of ergothioneine and the like
FR2581871A1 (en) PHENYTOINE-BASED SOLUTIONS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL APPLICATION THEREOF
BE879666A (en) NOVEL CEPHALOSPORINS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
IE830807L (en) Phenoxyalkylcarboxylic acid derivatives
EP0434546B1 (en) Process for the selective epoxidation of unsaturated (meth)acrylic compounds and new obtained bifunctional (meth)acrylates
FR2434392A1 (en) NEW DISULFIDE COMPOUND USEFUL IN COVALENCE CHROMATOGRAPHY
CA1190220A (en) Process for the manufacture of highly crystalline sodium cefoperazone
FR2368959A1 (en) COMPOSITIONS CONTAINING GUANIDINOALCANOIC ACID DERIVATIVES, USED AS A MEDICINAL PRODUCT
SE8304410L (en) CYCLOHEXYLCARBOXYLIC ACID DERIVATIVES AND SETS FOR THEIR PREPARATION
SU929630A1 (en) Process for producing di- or trioxydiphenyl sulfones
Uchino et al. Conversion of cyano-and hydroxo-cobalamin in vivo into co-enzyme form of vitamin B12 in the rat
RU94018525A (en) SUBSTITUTED 2-HYDROXY-3 [1- (1H-IMIDAZOL-4-IL) ALKYL] -BENZOLKARBOXIMIDAMIDES, METHODS OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION ON THEIR BASIS
EP0126013B1 (en) Cyclic dithioacetamides, process for their preparation and pharmaceutical compositions containing them
FI72313B (en) EXTERNAL REQUIREMENT FOR RACEMATING S- (CARBOXY-METHYL) - (R, S) -CYSTEIN I ISOMERER (B)
SU1371490A3 (en) Defoliation agent
Sherman et al. ENZYME PURIFICATION BY ADSORPTION: AN INVESTIGATION OF PANCREATIC AMYLASE1
EP0126012B1 (en) Pharmaceutical compositions containing symmetrical disulfides
US3980689A (en) N-(2,5-dichloro-4-thiocyanatophenyl)-β-alanine
EP4367124A1 (en) Process for preparing diosmin and flavonoid fraction
CA2328289A1 (en) Method for laminaribiose synthesis

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: GLAXO GROUP LTD

Effective date: 19851031